{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:04:39Z","timestamp":1787022279268,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.14310\/horm.2002.1754","type":"journal-article","created":{"date-parts":[[2018,2,11]],"date-time":"2018-02-11T18:35:42Z","timestamp":1518374142000},"page":"341-350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Endocrine sequelae of immune checkpoint inhibitors"],"prefix":"10.1007","volume":"16","author":[{"given":"Georgia","family":"Ntali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alevizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,30]]},"reference":[{"key":"16040341_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al, 2010 Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711\u2013723.","journal-title":"N Engl J Med"},{"key":"16040341_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al, 2015 Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23\u201334.","journal-title":"N Engl J Med"},{"key":"16040341_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","volume":"17","author":"SJ Antonia","year":"2016","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J, et al, 2016 Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol 17: 883\u2013895.","journal-title":"Lancet Oncol"},{"key":"16040341_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids MS, Kim HT, Bachireddy P, et al, 2016 Leukemia and Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 375: 143\u2013153.","journal-title":"N Engl J Med"},{"key":"16040341_CR5","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1001\/jamaoncol.2016.0775","volume":"2","author":"S George","year":"2016","unstructured":"George S, Motzer RJ, Hammers HJ, et al, 2016 Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: A subgroup analysis of a randomized clinical trial. JAMA Oncol 2: 1179\u20131186.","journal-title":"JAMA Oncol"},{"key":"16040341_CR6","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, et al, 2014 Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99: 4078\u20134085.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040341_CR7","doi-asserted-by":"crossref","unstructured":"McMillen B, Dhillon MS, Yong-Yow S, 2016 A rare case of thyroid storm. BMJ Case Rep, doi: 10.1136\/bcr-2016-214603.","DOI":"10.1136\/bcr-2016-214603"},{"key":"16040341_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1530\/EJE-10-0833","volume":"164","author":"L Min","year":"2011","unstructured":"Min L, Vaidya A, Becker C, 2011 Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164: 303\u2013307.","journal-title":"Eur J Endocrinol"},{"key":"16040341_CR9","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1089\/thy.2016.0562","volume":"27","author":"I Yamauchi","year":"2017","unstructured":"Yamauchi I, Sakane Y, Fukuda Y, et al, 2017 Clinical features of nivolumab-induced thyroiditis: A case series study. Thyroid 27: 894\u2013901.","journal-title":"Thyroid"},{"key":"16040341_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40425-017-0213-x","volume":"5","author":"U Khan","year":"2017","unstructured":"Khan U, Rizvi H, Sano D, Chiu J, Hadid T, 2017 Nivolumab induced myxedema crisis. J Immunother Cancer 5: 13.","journal-title":"J Immunother Cancer"},{"key":"16040341_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40425-017-0245-2","volume":"5","author":"JL Godwin","year":"2017","unstructured":"Godwin JL, Jaggi S, Sirisena I, et al, 2017 Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer 5: 40.","journal-title":"J Immunother Cancer"},{"key":"16040341_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I, 2013 Oncology meets immunology: the cancer-immunity cycle. Immunity 39: 1\u201310.","journal-title":"Immunity"},{"key":"16040341_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nri2131","volume":"7","author":"CG Fathman","year":"2007","unstructured":"Fathman CG, Lineberry NB, 2007 Molecular mechanisms of CD4+ T-cell anergy. Nat Rev Immunol 7: 599\u2013609.","journal-title":"Nat Rev Immunol"},{"key":"16040341_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nri1806","volume":"6","author":"W Zou","year":"2006","unstructured":"Zou W, 2006 Regulatory cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295\u2013307.","journal-title":"Nat Rev Immunol"},{"key":"16040341_CR15","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2007-11-125435","volume":"112","author":"B Kavanagh","year":"2008","unstructured":"Kavanagh B, O\u2019Brien S, Lee D, et al, 2008 CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 112: 1175\u20131183.","journal-title":"Blood"},{"key":"16040341_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/intimm\/dxm057","volume":"19","author":"T Okazaki","year":"2007","unstructured":"Okazaki T, Honjo T, 2007 PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19: 813\u2013824.","journal-title":"Int Immunol"},{"key":"16040341_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","volume":"170","author":"JA Brown","year":"2003","unstructured":"Brown JA, Dorfman DM, Ma FR, et al, 2003 Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170: 1257\u20131266.","journal-title":"J Immunol"},{"key":"16040341_CR18","unstructured":"https:\/\/doi.org\/www.uptodate.com\/contents\/toxicities-associated-with checkpoint-inhibitor-immunotherapy."},{"key":"16040341_CR19","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO, et al, 2015 Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33: 3193\u20133198.","journal-title":"J Clin Oncol"},{"key":"16040341_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M, 2017 Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13: 195\u2013207.","journal-title":"Nat Rev Endocrinol"},{"key":"16040341_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2217\/fon.15.222","volume":"12","author":"O Abdel-Rahman","year":"2016","unstructured":"Abdel-Rahman O, El Halawani H, Fouad M, 2016 Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncol 12: 413\u2013425.","journal-title":"Future Oncol"},{"key":"16040341_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2217\/imt-2016-0147","volume":"9","author":"YH Shang","year":"2017","unstructured":"Shang YH, Zhang Y, Li JH, Li P, Zhang X, 2017 Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. Immunotherapy 9: 261\u2013272.","journal-title":"Immunotherapy"},{"key":"16040341_CR23","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P, 2014 Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6: 230ra45.","journal-title":"Sci Transl Med"},{"key":"16040341_CR24","doi-asserted-by":"publisher","first-page":"T331","DOI":"10.1530\/ERC-17-0358","volume":"12","author":"P Cukier","year":"2017","unstructured":"Cukier P, Santini FC, Scaranti M, Hoff AO, 2017 Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer 12: T331\u2013T347.","journal-title":"Endocr Relat Cancer"},{"key":"16040341_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40618-016-0439-3","volume":"39","author":"G Vancieri","year":"2016","unstructured":"Vancieri G, Bellia A, Lauro D, 2016 Late-onset panhypopituitarism in a 72-year-old male patient treated with ipilimumab for metastatic melanoma: a case report. J Endocrinol Invest 39: 805\u2013806.","journal-title":"J Endocrinol Invest"},{"key":"16040341_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA, 2014 Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21: 371\u2013381.","journal-title":"Endocr Relat Cancer"},{"key":"16040341_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","author":"A Faje","year":"2016","unstructured":"Faje A, 2016 Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19: 82\u201392.","journal-title":"Pituitary"},{"key":"16040341_CR28","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, et al, 2017 Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 28: iv119\u2013iv142.","journal-title":"Annals of Oncology"},{"key":"16040341_CR29","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40618-015-0301-z","volume":"38","author":"PB Araujo","year":"2015","unstructured":"Araujo PB, Coelho MC, Arruda M, Gadelha MR, Neto LV, 2015 Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Invest 38: 1159\u20131166.","journal-title":"J Endocrinol Invest"},{"key":"16040341_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1586\/17512433.2016.1133289","volume":"9","author":"E Rossi","year":"2016","unstructured":"Rossi E, Sgambato A, De Chiara G, et al, 2016 Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. Expert Rev Clin Pharmacol 9: 419\u2013428.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"16040341_CR31","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/cen.13297","volume":"86","author":"DL Morganstein","year":"2017","unstructured":"Morganstein DL, Lai Z, Spain L, et al, 2017 Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 86: 614\u2013620.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"16040341_CR32","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1210\/jc.2016-2300","volume":"101","author":"J de Filette","year":"2016","unstructured":"de Filette J, Jansen Y, Schreuer M, et al, 2016 Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 101: 4431\u20134439.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040341_CR33","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, et al, 2017 Pembrolizumab-induced thyroiditis. Comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab 102: 2770\u20132780.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040341_CR34","doi-asserted-by":"crossref","unstructured":"Guaraldi F, La Selva R, Sam\u00e0 MT, et al, 2017 Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Invest, doi: 10.1007\/s40618-017-0772-1.","DOI":"10.1007\/s40618-017-0772-1"},{"key":"16040341_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","volume":"75","author":"R Gutzmer","year":"2017","unstructured":"Gutzmer R, Koop A, Meier F, et al, 2017 Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 75: 24\u201332.","journal-title":"Eur J Cancer"},{"key":"16040341_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/1346-8138.13028","volume":"43","author":"T Narita","year":"2016","unstructured":"Narita, T, Oiso, N, Taketomo, Y, et al, 2016 Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab. The Journal of Dermatology 43: 210\u2013214.","journal-title":"The Journal of Dermatology"},{"key":"16040341_CR37","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","volume":"21","author":"L Min","year":"2015","unstructured":"Min L, Hodi FS, Giobbie-Hurder A, et al, 2015 Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 21: 749\u2013755.","journal-title":"Clin Cancer Res"},{"key":"16040341_CR38","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","volume":"1","author":"L Min","year":"2013","unstructured":"Min L, Ibrahim N, 2013 Ipilimumab-induced autoimmune adrenalitis. Lancet Diabetes Endocrinol 1: e15.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"16040341_CR39","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","volume":"40","author":"S Bacanovic","year":"2015","unstructured":"Bacanovic S, Burger IA, Stolzmann P, Hafner J, Huellner MW, 2015 Ipilimumab-induced adrenalitis: A possible pitfall in 18F-FDG-PET\/CT. Clin Nucl Med 40: e518\u2013519.","journal-title":"Clin Nucl Med"},{"key":"16040341_CR40","doi-asserted-by":"crossref","unstructured":"Trainer H, Hulse P, Higham CE, Trainer P, Lorigan P, 2016 Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinol Diabetes Metab Case Rep, 16-0108.","DOI":"10.1530\/EDM-16-0108"},{"key":"16040341_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","volume":"310","author":"MR Zamani","year":"2016","unstructured":"Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N, 2016 PD-1\/PD-L and autoimmunity: A growing relationship. Cell Immunol 310: 27\u201341.","journal-title":"Cell Immunol"},{"key":"16040341_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","volume":"18","author":"MD Hellmann","year":"2017","unstructured":"Hellmann MD, Rizvi NA, Goldman JW, et al, 2017 Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18: 31\u201341.","journal-title":"Lancet Oncol"},{"key":"16040341_CR43","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000456540","volume":"10","author":"L Li","year":"2017","unstructured":"Li L, Masood A, Bari S, Yavuz S, Grosbach AB, 2017 Autoimmune diabetes and thyroiditis complicating treatment with nivolumab. Case Rep Oncol 10: 230\u2013234.","journal-title":"Case Rep Oncol"},{"key":"16040341_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40425-017-0245-2","volume":"5","author":"JL Godwin","year":"2017","unstructured":"Godwin JL, Jaggi S, Sirisena I, et al, 2017 Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer 5: 40.","journal-title":"J Immunother Cancer"},{"key":"16040341_CR45","doi-asserted-by":"crossref","unstructured":"Aleksova J, Lau PK, Soldatos G, McArthur G, 2016 Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. BMJ Case Rep, bcr2016217454.","DOI":"10.1136\/bcr-2016-217454"},{"key":"16040341_CR46","doi-asserted-by":"publisher","first-page":"1039.e5","DOI":"10.1016\/j.ajem.2017.02.048","volume":"35","author":"MA Win","year":"2017","unstructured":"Win MA, Thein KZ, Qdaisat A, Yeung SJ, 2017 Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am J Emerg Med 35: 1039.e5\u20131039.e7.","journal-title":"Am J Emerg Med"},{"key":"16040341_CR47","doi-asserted-by":"crossref","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al, 2017 Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA Oncol, doi: 10.1001\/jamaoncol.2017.3064.","DOI":"10.1001\/jamaoncol.2017.3064"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1754.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.14310\/horm.2002.1754\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1754.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T10:40:11Z","timestamp":1739097611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.14310\/horm.2002.1754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["16040341"],"URL":"https:\/\/doi.org\/10.14310\/horm.2002.1754","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"2 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}